Brand Intelligence Graph
Company Overview
About Scribe Therapeutics
Scribe Therapeutics was co-founded by Jennifer Doudna — who shared the 2020 Nobel Prize in Chemistry for CRISPR-Cas9 invention — and develops the ELXR platform: a CasX-based epigenetic silencing system that reduces gene expression without making permanent DNA cuts. The company has raised $100 million in Series B financing with strategic partnerships with Sanofi and Eli Lilly. The lead program, STX-1150, targets PCSK9 for durable LDL-C reduction and is projected to receive an IND and enter human trials in mid-2026.
Business Model & Competitive Advantage
The epigenetic silencing approach is ELXR's primary clinical safety differentiator from CRISPR gene editing: rather than cutting and permanently altering DNA (which CRISPR-Cas9 does), ELXR uses CasX to recruit epigenetic machinery that methylates the target gene's promoter — silencing transcription without changing the genetic sequence. This approach is potentially reversible and avoids the permanent off-target editing risks that regulatory agencies scrutinize most carefully in gene editing clinical trials.
Competitive Landscape 2025–2026
PCSK9 inhibition is one of the most commercially validated mechanisms in cardiovascular medicine: Repatha (evolocumab) and Praluent (alirocumab) generate $2+ billion annually. A one-time epigenetic silencing that achieves equivalent LDL-C reduction without monthly injection could transform the $2+ billion injectable PCSK9 market into a one-time treatment.
Key Differentiators
Emerging Innovator
Scribe Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Scribe Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Scribe Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Scribe Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Scribe Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →